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Walter Schwartz7, Adam Jan Wronecki8 and Ilse Vejborg9
Abstract
Background: In Denmark, national roll-out of a population-based, screening mammography program took place in
2007–2010. We report on outcome of the first four biennial invitation rounds.
Methods: Data on screening outcome were retrieved from the 2015 and 2016 national screening quality reports.
We calculated coverage by examination; participation after invitation; detection-, interval cancer- and false-positive
rates; cancer characteristics; sensitivity and specificity, for Denmark and for the five regions.
Results: At the national level coverage by examination remained at 75–77%; lower in the Capital Region than in
the rest of Denmrk. Detection rate was slightly below 1% at first screen, 0.6% at subsequent screens, and one
region had some fluctuation over time. Ductal carcinoma in situ (DCIS) constituted 13–14% of screen-detected
cancers. In subsequent rounds, 80% of screen-detected invasive cancers were node negative and 40% ≤10 mm.
False-positive rate was around 2%; higher for North Denmark Region than for the rest of Denmark. Three out of 10
breast cancers in screened women were diagnosed as interval cancers.
Conclusions: High coverage by examination and low interval cancer rate are required for screening to decrease
breast cancer mortality. Two pioneer local screening programs starting in the 1990s were followed by a decrease in
breast cancer mortality of 22–25%. Coverage by examination and interval cancer rate of the national program were
on the favorable side of values from the pioneer programs. It appears that the implementation of a national
screening program in Denmark has been successful, though regional variations need further evaluation to assure
optimization of the program.
Keywords: Breast cancer, Ductal carcinoma in situ., Screening., Mammography.
Background
Breast cancer has been the most common cancer disease
in Danish women ever since national cancer registration
started in 1943. However, the disease has been on a
steady increase with a doubling of the age-standardised
rate (Nordic standard population) from 69 per 100,000
in the early 1940s to 145 today [1]. This development is
not surprising, given that the risk of breast cancer is
closely related to the woman’s reproductive history.
Women born in 1929–1947 reported an average age of
menarche at 13.56 years [2], while this had decreased to
13.30 years for women born primarily in 1960–1980 [3].
At the same time, the age at first birth has increased, it
was 23 years around 1960 and 29 years in 2015 [4]. The
proportion of obese women increased from 1994 to
2010 [5]. With this considerable extension of the time
window from menarche to first birth and with increased
obesity, Danish women became more vulnerable to
breast cancer, and primary prevention is difficult.
Since the late 1970s, node negative and moderately
node positive breast cancers dominated the increasing
incidence, probably as a result of emerging breast aware-
ness [6]. Furthermore, new treatment modalities in the
form of staging with axillary lymph node dissection; and
hormonal and adjuvant chemotherapy treatment have
helped to keep breast cancer mortality in control. Breast
cancer mortality was at the level of 45 per 100,000 in
the early 1940s and only increased to 51 per 100,000 in
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the mid 1990s, where after a decrease has been observed
to 33 per 100,000 in 2014 [1]. However, breast cancer
still causes 1100 deaths per year; being the second cause
of cancer death in Danish women.
In the 1980s, a number of randomized controlled trial
– first of all from Sweden – showed that screening
mammography with early detection of small breast
cancers could help to reduce breast cancer mortality [7].
In 2003, the European Union recommended population-
based breast cancer screening [8]. In Denmark, this
development led to the start of some regional screening
programs in the early 1990s, and to national roll-out of
screening in 2007–2010.
The long-tem purpose of breast cancer screening is to
reduce breast cancer mortality [9]. When a screening
program is implemented, it is, however, necessary to
know relatively quickly whether or not the program is
on the right track. The randomized controlled trials
showed that short-term indicators of the screening
program like the interval cancer rate, rate of screen-
detected cancers, etc. correlated well with the later
decline in breast cancer mortality [10]. It has therefore
become standard to evaluate the early outcome of a
screening program based on a set of short term indica-
tors [11]. We report here on the short-term outcomes of
the national Danish screening program.
Methods
Breast cancer screening program
In the 1990s, Denmark was divided into 16 administra-
tive areas. A population-based screening program started
in one of these areas; the municipality of Copenhagen;
in April 1991 [12]. This was followed by programs in the
county of Funen in November 1993 [13], and in the
municipality of Frederiksberg in June 1994. Women
aged 50–69 years were personally invited to biennial
screening at dedicated screening clinics being stationary
or mobile. One invitation, eventually followed by two
reminders or another invitation, were sent to all women
unless they had informed the program that they did not
want to be invited. Furthermore women terminally ill, in
breast cancer treatment/control, or with mammography
within the last 12 months were not invited if this infor-
mation was known to the screening program.
Trained radiographers took the mammograms, and
screening did not include clinical breast examination.
Two-view mammography was used at the first examin-
ation, and during the first ten years of the programs,
women with fatty breast tissue would be scheduled for
one-view at next screen, whereas women with mixed/
dense tissue would be scheduled for two-view mammog-
raphy. From around 2001, two-view mammography was
used in all examinations. Mammograms were read
independently by two trained radiologists. Women with
suspicious finding were recalled for diagnostics at the
hospital radiology departments. In 2006, the programs
switched from analog to digital mammography.
In 1999, it became mandatory for Danish counties to
offer breast cancer screening, but it was up to the minis-
ter of health to decide on the time of implementation of
this law [14]. Screening started in the small county of
Bornholm in 2001, and in Zealand county in 2004. In
2005, the breast cancer screening program in the muni-
cipality of Copenhagen was reported to have been
followed by a 25% reduction in breast cancer mortality
in the target population and a 37% reduction amongst
participants [15]. Based on these results, the minister of
health required that the new regions (from 1 January
2007) should start breast cancer screening before the
end of 2007 and that the rollout should be completed at
the end of 2009 [16]. A national quality database was
implemented, and a steering committee was appointed
with the responsibilities to monitor quality and to draw
up national clinical guidelines for the screening [17].
The national screening program was in all aspects orga-
nized similarly to the pioneer programs.
Danish quality assurance Data Base on mammography
screening – DKMS
The breast cancer screening program is monitored
annually based on 11 quality assurance indicators [11]
inspired by the European guidelines [18]: radiation dose;
participation after invitation; adherence to screening
intervals; recall; interval cancers; invasive cancers as pro-
portion of screen-detected cancers (invasive + ductal
carcinoma in situ (DCIS)); node negative as proportion
of invasive cancers; invasive cancers ≤10 mm as propor-
tion of invasive cancers; benign vs. malignant operations;
and response time. Using a slightly modified version of
these indicators, we report here on: coverage by examin-
ation; participation after invitation; detection rate; inter-
val cancer rate; and cancer characteristics (proportion
invasive, node-negative, and size). From the data we
furthermore calculated number of false positive screens;
sensitivity; and specificity. The reported data covered the
first four approximately biennial invitation rounds. Inter-
val cancer data were not available for the fourth round.
Data in the DKMS on the target population for screen-
ing are retrieved from the Central Population Register
(CPR) including all persons with a permanent address at
any time since 1968. Data on invitations to screening are
retrieved from the regional booking systems, which are
based on always updated versions of CPR. Data on
participation in screening and on screening outcome are
retrieved from the Danish Patient Register. This register
includes information on all out-and inpatient contacts to
Danish hospitals. As all screening, assessment of women
with suspicious screens, and eventual treatment take
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place in hospitals, all contacts related to the screening
program will be recorded in the Danish Patient
Register. Data on screen-detected and interval breast
cancers are retrieved from the Danish Pathology
Register (Patobank), which records data on all
pathology specimens from Denmark. Opportunistic
screening is rare in Denmark [19], and data on mam-
mography outside the program are not included in
the DKMS. Annual DKMS reports have been
published since 2010. However, due to updates and
correction of data files reported numbers vary some-
what from one report to another. We have used data
from the reports from 2015 [20] and 2016 [21],
respectively. The DKMS data are published without
age-specification. This should, however, not affect the
results, as the age-distribution for women aged 50–69 years
varies for each 5-year age-group by only +/−1% across the
five Danish regions [22].
Statistics
The target population for screening is defined as women
aged 50–69 years and living in a given region at the start
of an invitation round; in practice these dates have been
defined as 1 January 2008 for first, 2010 for second,
2012 for third, and 2014 for fourth round. Invited to
screening are women aged 50–69 years defined in run-
ning age during the invitation round meaning that
women start to be invited when they turn 50 years and
end being invited when they turn 70 years. The open
population of invited women could thus be larger than
the target population. Some invitation rounds further-
more lasted longer than 24 months, Additional file 1:
Table S1. However, in some rounds in the Southern
Denmark and the Capital regions women who had not
responded to three previous invitations or reminders
were excluded from invitation in the following invitation
round. Here we report coverage by examination
calculated as number of screened women divided by the
target population, and participation after invitation as
number of screened women divided by the number of
invited women.
Screened women with abnormal findings (positive
screens) were referred for assessment, while women with
normal findings (negative screens) were returned to rou-
tine screening. A screen-detected cancer was defined as
a woman with a positive screen and diagnosed with inva-
sive breast cancer or ductal carcinoma in situ (DCIS)
within the next 6 months. Interval cancer was defined as
invasive breast cancer diagnosed in women with negative
screen within 24 months of the screening date (or before
next screen), and in women with positive screen within
6–23 months of the sceening date. A false-positive
screen was a women with a positive screen and no
screen-detected cancer. The very small number of
women with invasive breast cancer 6–23 months after a
positive screen would be counted both as interval can-
cers and as false-positives, but it was not possible from
the published data to separate out this very small group.
The screen-detection rate was: ((women with screen-
detected invasive cancer +DCIS)/screened women). The
false-positive rate: ((screen-positive women-(women with
screen-detected invasive cancer +DCIS))/screened women).
Interval cancer rate was: (Interval cancers/(interval cancers
+ screen-detected invasive cancer +DCIS)). Sensitivity was:
(Screen-detected cancer/(Screen-detected cancer + interval
cancers)). Specificity was: ((Screened women-(Screen-de-
tected cancer + interval cancers)-(false-positive))/(Screened
women-(Screen-detected cancer + interval cancers)). The
cumulative false-positive risk after four rounds of screening
as calculated as [1-(1-fp1)(1-fp2)(1-fp3)(1-fp4)], where fpi
was the false-positive rate in a given invitation round [23].
95% confidence intervals (CI) were calculated under the
assumption of a binomial distribution of the numerator.
Ethics
All data in this paper were quoted from publicly
available databases.
Results
Coverage by examination has remained stable at 75–77%
throughout the first four rounds of the Danish screening
mammography program, Table 1. While most of the re-
gions had a coverage by examination fluctuating around
the national average, the Capital Region was systematic-
ally below the average, being 68.0% (95% CI, 67.8–68.2)
at its lowest in the second invitation round 2010–2011,
Additional file 2: Table S2, Fig. 1. Participation after
invitation was 77–84%.
The detection rate was 0.93% in the first invitation
round which for the majority of screened women was
the prevalence screen, and the detection rate fluctuated
between 0.61 and 0.67% the the next three invitations
rounds. There was limited regional difference in the de-
tection rate during the first round. However, in the third
round the Capital Region had a detection rate of 0.77%
(95% CI, 0.73–0.82), and considerable variation was seen
in the detection rate in Region Zealand from 0.69% in
the third round to 0.53% (95% CI, 0.48–0.58) in the
fourth round, Fig. 2. The proportion of DCIS out of all
screen-detected cases was stable over time being 13% in
the first invitation round and 14% in the fourth. The re-
gional variations were limited apart from fluctuations
over time the in the small North Denmark Region. At
the national level, the false-positive rate was fairly stable
varying from 1.88% (95% CI, 1.84–1.92) to 2.08% (95%
CI, 2.04–2.12) between rounds, Table 1. Region North
Denmark was, however, systematically above the other
regions, with false-positive rates varying from 2.7% (95%
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CI, 2.6–2.9) to 3.2% (95% CI, 3.0–3.3), Additional file 3:
Table S3.
At the national level, invasive breast cancer as propor-
tion of screen-detected cancers remained at 86–87%
throughout the four rounds, Table 1, but during the first
round there was a variation from 96% (95% CI, 93–97)
in North Denmark to 85% (95% CI, 83–87) in South
Denmark; a variation that diminished over time,
Additional file 3: Table S3. As expected, the proportions
of lymph node negative and small cancers were lower in
the first round than later; 70% (95% CI, 68–71) and 36%
(95% CI, 34–39), respectively. These proportions had
increased to 80% (95% CI, 79–82) and 40% (95% CI,38–42),
respectively, in the fourth round, Additional file 4: Table S4.
As the first round was the prevalence screen for most
women, the interval cancer rate at the national level was
low, 18% (1032/(4724 + 1023), and the sensitivity was
high, 82% (100–18%), Table 1. In the second and third
rounds these numbers had changed to 26–29% and 71–74%,
respectively. The specificity remained at 98% throughout the
three rounds. There was, however, some variation across
regions in sensitivity and specificity. The North Denmark
Region had systematically lower specificity than the other
Table 1 Overview of performance indicators in screening mammography in Denmark 2008–2015
Performance indicator Invitation round
First 2008–2009% Second 2010–2011% Third 2012–2013% Fourth 2014–2015%
Coverage of examination 75.4 (75.3–75.5) 75.0 (74.8–75.1) 76.7 (76.6–76.8) 76.4 (76.3–76.5)
Participation after invitation 76.4 (76.3–76.5) 81.8 (81.7–81.9) 84.3 (84.3–84.4) 82.1 (82.0–82.2)
Detection rate 0.93 (0.91–0.96) 0.62 (0.60–0.64) 0.67 (0.65–0.69) 0.61 (0.59–0.64)
False-positive rate 2.04 (2.00–2.08) 2.08 (2.04–2.12) 2.07 (2.03–2.11) 1.88 (1.84–1.92)
Invasive 87.5 (86.5–88.4) 86.3 (85.0–87.5) 86.4 (85.2–87.4) 85.8 (84.5–86.9)
DCIS 12.6 (11.6–13.5) 13.7 (12.5–15.0) 13.6 (12.6–14.8) 14.2 (13.1–15.5)
Lymph node neg 69.8 (68.4–71.2) 74.5 (72.8–76.2) 78.2 (76.7–79.6) 80.4 (78.8–81.8)
Small tumor 36.1 (34.4–37.8) 40.1 (38.2–42.1) 39.8 (38.0–41.5) 40.1 (38.3–42.0)
Interval cancer rate 17.9 (16.9–19.1) 28.9 (27.3–30.5) 26.3 (24.9–27.8) NA
Sensitivity 82.1 (81.1–83.1) 71.2 (69.8–72.5) 73.7 (72.5–74.8) NA
Specificity 97.9 (97.9–98.0) 97.9 (97.9–97.9) 97.9 (97.9–98.0) NA
Notes:
NA not available
Percent and 95% confidence intervals
Fig. 1 Coverage in screening mammography in Denmark 2008–2015
by invitation round and region. Percent and 95% confidence intervals.
Notes: 1 South Denmark omitted in 1st round because only 70% of
target population was invited. 2 Zealand omitted in 2nd round
because the round was stopped before time to synchronize time
periods across regions
Fig. 2 Detection rate in screening mammography in Denmark
2008–2015 by region and invitation round. Percent and 95%
confidence intervals
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regions. In the third invitation round, the specificity in the
North Denmark Region was 97.0% (95% CI 96.9–97.1) as
compared with 97.9% (95% CI 97.7–98.0) for all of
Denmark, Additional file 5: Table S5. The outlier position of
the North Denmark region is illustrated in Fig. 3.
Discussion
Main findings
Three quarters of Danish women followed the screening
mammography program. Slightly below 1% of these
women had a breast cancer (invasive or DCIS) detected
at their first screen, and around 0.6% in subsequent
screens. The proportion of DCIS remained constant 13–
14% during the four invitation rounds; and in subse-
quent rounds 75–80% of the screen-detected invasive
breast cancers were lymph node negative and 40% had a
diameter equal to or below 10 mm. The screening pro-
gram thus detected mainly invasive, lymph-node nega-
tive breast cancers with a high proportion of small
cancers.
The false-positive rate remained around 2%, indicating
that only a very small proportion of screened women
underwent assessment without having breast cancer. On
the other hand in subsequent rounds, a negative screen
was no guarantee against breast cancer developing
shortly after or having been overlooked in the first place.
Three out of 10 breast cancers in screened women were
diagnosed as interval cancers.
However, some regional differences were seen even in
this population with only a total of 700,000 screen-
targeted women. As seen in other urban settings [24],
the coverage was relatively low in the Capital Region.
This was in particular the case in the second round,
where the coverage was 68% in the Capital Region as
compared to the national average of 75%. The second
round coincided with the publication of a study that
claimed that screening lead to heavy overdiagnosis, and
that one third of breasts were removed without reason
[25]. Women in the Capital Region may have been more
sensitive than other women to negative messages
reported in the media. It is noteworthy that coverage in
the Capital Region in the third and fourth rounds were
back to the higher level from the first round.
The detection rate was surprisingly high in the Capital
Region in the third round, 0.77% versus the national
average of 0.67%. This was probably due a longer time
interval between screens; the third invitation round
lasted 28 months, and some women screened in the
third round had skipped screening in the second round.
In Region Zealand the detection rate fluctuated over
time, in contrast to the situation in the other regions.
Worrisome was the low detection rate of 0.53% in the
third round where the national average was 0.61%. One
possible explanation could be that the detection rate was
high in the third round and that the prevalent pool of
breast cancers was depleted at that time. But this should
then have been followed by a high sensitivity which was
not the case, Additional file 4: Table S4. The region has
suffered from shortage of experienced radiologists. It
remains to be seen what the sensitivity will be in Region
Zealand after the fourth round.
The proportion of women with a false-positive screen
was higher in the North Denmark Region than in
Denmark on average; the cumulative risk being 11.4% as
compared with the average of 7.9%. The region also had
a conservative diagnostic practice, as both the detection
rates and the proportion of DCIS were generally in the
low end of the spectrum.
Strengths and weaknesses
The DKMS data are nationwide and based on individu-
ally registered events. Several circumstances have, how-
ever, complicated the reporting. First, Denmark does not
have a national invitation database. In order to follow
the fate of an individual woman, data from the regional
booking systems have to be linked with data from the
Danish Patient Register and the Patobank; and these
matches were not always perfect. It is though unlikely
that this would have affected the results; e g. in the first
invitation round a total of 509,932 women were screened
and results were missing for only 88 of these women.
Second, an invitation round should ideally have a length
of 24 months. But due to lack of manpower this has not
always been possible, and even the fourth round lasted
Fig. 3 Sensitivity versus 1-specificity in screening mammography in
Denmark 2015 by region and invitation round
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27 months in 3 of the 5 regions. This led to problems
with allocation of data to the correct round; reflected in
changes in numbers from one annual DKMS report to
the next. For this reason only the latest updated data
were quoted in this paper.
Perspective for reduction in breast cancer mortality
Given the correlation observed in the randomised
controlled trial between favourable outcomes of the
short-term indicators and the later decline in breast
cancer mortality [10], one may ask whether the Danish
national program is on the right track. Here it might be
reasonably to compare with the outcomes of the two
pilot programs. There is, however, some confusion in
the literature about the impact of these two pilot pro-
grams on breast cancer mortality and overdiagnosis.
Before turning to a comparison with the present national
program, it is therefore necessary to understand these
seemingly contradictory results from the pilot programs.
The fact that two Danish administrative areas introduced
breast cancer screening up to 17 years before the rest of
Denmark constituted almost a “natural experiment”, and
this has provided the basis for several evaluations of the
effect of screening. Using individually linked cohort data
from the Copenhagen program, Olsen et al. [15] found that
breast cancer mortality in Copenhagen had decreased by
25% more than expected in the absence of screening; and
Njor et al. [26] found a decrease of 22% for the Funen pro-
gram. Using routine breast cancer mortality data from fixed
age-groups, Jørgensen et al. [27] concluded that they “were
unable to detect any effect of the Danish screening pro-
grammes on breast cancer mortality”.
There is, however, explanations for these seemingly
contradictory results. First, the routine data used by
Jørgensen et al. included breast cancer deaths from
women diagnosed with breast cancer prior to the start of
the screening program, and these women had no chance
to benefit from screening. Olsen et al. used incidence-
based mortality including only deaths from breast cancer
in women diagnosed after the start of the screening pro-
gram, and thus having had a chance to benefit from
screening. Second, Jørgensen et al. looked only at average
annual change in the trends of breast cancer mortality be-
fore and after start of screening. They left out observations
from the first 7 years after start of the screening programs,
and thus ignored changes in breast cancer mortality dur-
ing this period. In fact, a recalculation of the data reported
by Jørgensen et al. showed a decline of 13% in breast can-
cer mortality in the screening areas as compared with the
decline in the non-screening areas [28]. Given that the
Jørgensen et al. data were contaminated with breast can-
cer deaths in women diagnosed prior to screening, this
13% decline is fairly much in line with the 22–25% decline
observed by Olsen et al. and Njor et al. in the non-
contaminated data.
Overdiagnosis has been studied also based on the early
Danish data. Using individually linked data from cohorts
of women offered screening and followed for a mini-
mum of 8 years after end of screening age, Njor et al.
[29] estimated overdiagnosis to amount to 2.3%. Using
routine data from fixed age-groups, Jørgensen et al. [25, 30]
concluded that “1 in every 3 women aged 50 to 69 years
diagnosed with breast cancer was overdiagnosed”. However,
screening introduces a dynamic in the incidence of breast
cancer with a prevalence peak, an artificial aging, and a
compensatory dip [31, 32]. This dynamic is captured
correctly only by following the cohorts of screened women.
With the method used by Jørgensen et al., they were unable
to capture the compensatory dip correctly. Jørgensen et al.,
furthermore measured differences instead of proportions,
and thus inflated their estimate of overdiagnosis by
geographical differences in breast cancer incidence prior to
the introduction of screening [33].
The differences between the study approaches used by
Olsen et al. and Njor et al. and the one used by Jørgensen
et al. stress the superiority of using individually linked co-
hort data as opposed to routine statistics data in evaluation
of screening outcomes. The most accurate estimate of the
decline in breast cancer mortality in the pilot programs is
therefore 25% for Copenhagen and 22% for Funen. The
short-term indicators from the first four invitation rounds
of the two Danish pilot programs in the municipality of
Copenhagen ([12, 34] + unpublished material) and the
county of Funen ([13, 34] + unpublished data) are summa-
rized in Table 2.
Table 2 Coverage, interval cancer and false positive rates
during the first four invitation rounds of the Danish pioneer
screening mammography programs in the municipality of
Copenhagen (1991–1998) and the county of Funen (1994–2001)
Invitation round
First % Second % Third % Fourth %
Copenhagen
Coverage by
examination
71 (70–71) 63 (63–64) 63 (62–63) 63 (63–64)
Interval cancer
rate
14 (11–17) 28 (23–35) 27 (22–34) 33 (27–39)
False positive
rate
5.5 (5.2–5.7) 3.9 (3.6–4.1) 2.5 (2.3–2.7) 2.4 (2.2–2.6)
Funen
Coverage by
examination
85 (84–85) 83 (83–84) 82 (82–83) 84 (84–84)
Interval cancer
rate
18 (15–22) 34 (30–39) 39 (34–44) 32 (28–37)
False positive
rate
1.7 (1.6–1.9) 1.1 (1.0–1.2) 1.1 (1.0–1.2) 1.0 (0.9–1.1)
Percent and 95% confidence intervals
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In the randomised controlled trials a low interval can-
cer rate, a high screen-detection rate, a low proportion
of stage II+ tumors, and a high proportion of small tu-
mors were predictors of a later decline in breast cancer
mortality [10]. At the population level one might add
coverage by examination to this list of predictors.
Copenhagen had a lower interval cancer rate than Funen
during the first three rounds, which can probably ex-
plain why screened women in Copenhagen had a larger
decrease in breast cancer mortality than screened
women from Funen. Funen on the other had higher
coverage by examination, and the two pioneer programs
ended up with largely similar decreases in breast cancer
mortality for screen-targeted women. It should be
taken into account that breast cancer patients in
Funen already prior to the implementation of screen-
ing had a better survival then breast cancer patients
in the rest of Denmark [35], and that the Funen
program deliberately aimed for a lower false positive
rate than found in the start of the Copenhagen pro-
gram, Table 2.
In the first four invitation rounds of the national pro-
gram, the coverage by examination has been almost at the
average of the coverage by examination in the pilot pro-
grams, Fig. 4. During the first three invitation rounds the
interval cancer rate has been in line with the rate observed
in the Copenhagen program. This means that the national
program has both avoided the low coverage by examin-
ation in the pilot Copenhagen program and the high inter-
val cancer rate in the pilot Funen program. On this basis
one might expect that the national program will also re-
sult in a reduction in breast cancer mortality. Thorough
cohort studies on incidence-based mortality are needed in
order to investigate this. Women in the national program
paid a price in terms of false-positive screens exceeding
the low level in the pilot program in Funen.
Furthermore, as the majority of screen-detected
breast cancers are node negative, Additional file 4:
Table S4, women are spared axillary dissection. Given
that 40% of screen detected tumors were ≤10 mm
and that 80% were lymph node negative, a significant
proportion of screen-detected tumors are expected to
be low risk not in need of chemotherapy, but the
DKMS data are too sparse on tumor biology to esti-
mate the precise proportion.
Conclusion
Fulfillment of short-term quality indicators is a pre-
requisite for a screening mammography program to
achieve its purpose of reducing breast cancer mortal-
ity [10]. Our study showed that even within the small
Danish population the variations in both screen-
detection and false-positives rates were surprisingly
large but all regions are working quite well in accord-
ance with European and national guidelines. Screen-
ing mammography is a delicate balance between
benefits and harms [36], and the Danish experiences
illustrate the importance of close monitoring of short-
term quality indicators.
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